For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Aura Biosciences, Inc.

USPTO Granted Patents = 12

CIPO Patents = 1

EPO Patents = 6

Forward Citations = 89

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Elisabet De Los Pinos (12 out of 13 patents)

Rhonda C Kines (9 out of 10 patents)

John MacDougall (4 out of 5 patents)

4. John T Schiller (4 out of 34 patents)

5. Pierre L Coursaget (3 out of 3 patents)

6. Maxime J J Fleury (3 out of 3 patents)

7. Nicolas Combelas (3 out of 3 patents)

8. Antoine A Touzé (2 out of 2 patents)

9. Antoine A Touźe (1 out of 1 patent)

10. John Todd Schiller (1 out of 1 patent)

11. Stephen A Monks (0 patent)

12. Antoine A Touze (0 patent)

13. Maxime J Fleury (0 patent)

14. Stephen A Monks (0 patent)

12 patents: Sort by Forward Citations

1. 12589165 - Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors (2026-03-31),

2. 11806406 - Virus-like particle conjugates for diagnosis and treatment of tumors (2023-11-07),

3. 11110181 - Virus-like particle conjugates for diagnosis and treatment of tumors (2021-09-07),

4. 10688172 - HPV particles and uses thereof (2020-06-23),

5. 10596275 - Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells (2020-03-24),

6. 10588984 - Virus-like particle conjugates for diagnosis and treatment of tumors (2020-03-17),

7. 10300150 - Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells (2019-05-28),

8. 10179168 - HPV particles and uses thereof (2019-01-15),

9. 10117947 - Virus-like particle conjugates for diagnosis and treatment of tumors (2018-11-06),

10. 9855347 - Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells (2018-01-02),

11. 9724404 - HPV particles and uses thereof (2017-08-08),

12. 9700639 - Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells (2017-07-11),

Aura Biosciences, Inc. is a biotechnology company focused on developing therapies for rare cancers that have high unmet medical needs. The company's lead product candidate is AU-011, a viral nanoparticle conjugate that is being evaluated in clinical trials for the treatment of ocular melanoma. Aura Biosciences is committed to creating innovative treatments that improve outcomes for patients with rare and aggressive cancers.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

12 Patents

#169 in Boston, MA

#1,545 in Massachusetts

#25,526 in US

#48,090 in the World

Boston, MA, United States of America

Aura Biosciences, Inc.

Forward Citations = 89

11 inventors:

Elisabet De Los Pinos (12 out of 13 patents)

Rhonda C Kines (9 out of 10 patents)

John MacDougall (4 out of 5 patents)

4. John T Schiller (4 out of 34 patents)

5. Pierre L Coursaget (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…